Fig. 5From: ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE studyOutcome measures recorded at the index date (week 0) and during benralizumab treatment, up to week 48. A FEV1 (L); B FVC (L); C ACT scoreBack to article page